Gefitinib
AstraZeneca
EGFR
RY
NSCLC
2003–
2005,
2015
Gilteritinib
Astellas
FLT3
RY
AML
2018
Ibrutinib
Pharmacyclics
and J&J
Bruton tyrosine kinase
NRY Mantle cell lymphoma, CLL,
lymphoplasmacytic lymphoma, marginal zone
B-cell lymphoma
2013
Imatinib
Novartis
BCR-ABL, KIT, PDGFR
NRY CML, ALL (Ph
+
), aggressive systemic
mastocytosis, CEL, DFSP, HES, GIST,
MDS/MDP
2001
Lapatinib
GSK
EGFR, ErbB2
RY
Breast cancer
2007
Larotrectinib Bayer
TRK
RY
Solid tumors with NTRK gene fusion proteins
2018
Lenvatinib
Eisai
VEGFR1/2/3, PDGFR, FGFR, KIT, RET
RY
Differentiated thyroid cancer
2015
Lorlatinib
Pfizer
ALK
RY
NSCLC (ALK
+
)
2018
Midostaurin
Novartis
FLT3, PDGFR, VEGFR2, PKC
RY
AML, mastocytosis, mast cell leukemia
2017
Neratinib
Puma
ErbB2/HER2
RY
Breast cancer (HER2
+
)
2017
Netarsudil
Aerie Pharm.
RRH kinase
NRS/
T
Glaucoma
2018
Nilotinib
Novartis
BCR-ABL, PDGFR, DDR1
NRY CML (Ph
+
)
2007
Nintedanib
Boehringer
Ingelheim
FGFR1/2/3, PDGFRα/β, VEGFR1/2/3, Flt3
RY
Pulmonary
fibrosis, idiopathic
2014
Osimertinib
AstraZeneca
EGFR T970M
RY
NSCLC
2015
Palbociclib
Parke-Davis
CDK4/6
S/T
Breast cancer (ER
+
/ HER2
+
)
2015
Pazopanib
GSK
VEGFR1/2/3, PDGFRα/β, FGFR1/3, KIT, LCK,
FMS, LTK
RY
RCC, soft tissue sarcomas
2009
Ponatinib
Ariad
BCR-Abl, BCR-ABL
T315I
, VEGFR, PDGFR,
FGFR, EphR, SRC family kinases, kit, RET,
TIE2, Flt3
NRY CML, ALL (Ph+)
2012
Regorafenib
Bayer
VEGFR1/2/3, BCR-Abl, BRAF, BRAF (V600E),
KIT, PDGFRα/β, RET, FGFR1/2, TIE2, EPH2A
RY
CRC, HCC, GIST
2012
(continued)
Exploiting Kinase Inhibitors for Cancer Treatment: An Overview of Clinical. . .
129